Suvanto-Luukkonen E, Sundström H, Penttinen J, Läärä E, Pramila S, Kauppila A
Kainuu Central Hospital, Department of Obstetrics and Gynecology, Oulu, Finland.
Maturitas. 1997 Apr;26(3):211-7. doi: 10.1016/s0378-5122(96)01100-0.
To evaluate the bleeding patterns and clinical compliance associated with postmenopausal amenorrhea-inducing forms of hormone replacement therapy using either percutaneous estradiol-gel and a levonorgestrel-releasing intrauterine device or an oral/vaginal natural progesterone.
Sixty postmenopausal women with an intact uterus were followed over 12 months in this open, non-randomised, parallel group study. All patients continuously received a gel containing 1.5 mg of estradiol daily. The women were divided into three groups on the basis of progestin administration. Twenty women (group I) had a levonorgestrel-releasing device (LNG-IUD) inserted at the beginning of the study. Twenty-one women (group II) received oral natural micronised progesterone (oral P) 100 mg daily during 25 calendar days each month, and 19 women (group III) used vaginal natural micronised progesterone (vaginal P) 100-200 mg daily during 25 calendar days each month (higher dose if spotting occurred). Clinic visits were at 0, 3, 6 and 12 months. Bleeding patterns were recorded by the patient in a diary and clinical compliance was evaluated at control visits during the treatment. Symptoms were recorded using a modified Kuppermann index. The serum estradiol concentration was determined at the 0, 6 and 12 month control visits.
80% (n = 16) of the patients in the LNG-IUD group, 67% (n = 14) in the oral P group II and 53% (n = 10) in the vaginal P group were without bleeding at 12 months. Spotting was common during the first 3 months. Symptom relief was good in each group. The LNG-IUD did not cause any serious side-effects. Compliance was good for LNG-IUD and oral progesterone but not for vaginal progesterone.
Percutaneous estradiol-gel associated with LNG-IUD is an appropriate method of hormone replacement therapy. The combination of oral natural progesterone with estradiol-gel is also useful, although bleeding episodes complicated the treatment in one third of the patients. The vaginal administration of natural progesterone was impractical due to bleeding disorders.
评估采用经皮雌二醇凝胶与左炔诺孕酮宫内节育器或口服/阴道天然孕酮的绝经后诱导闭经形式的激素替代疗法的出血模式和临床依从性。
在这项开放、非随机、平行组研究中,对60名子宫完整的绝经后妇女进行了12个月的随访。所有患者每天持续接受含1.5毫克雌二醇的凝胶。根据孕激素给药情况将这些女性分为三组。20名女性(第一组)在研究开始时植入了左炔诺孕酮释放装置(LNG-IUD)。21名女性(第二组)每月在25个日历日中每天口服天然微粉化孕酮(口服P)100毫克,19名女性(第三组)每月在25个日历日中每天使用阴道天然微粉化孕酮(阴道P)100 - 200毫克(如果出现点滴出血则使用更高剂量)。门诊就诊时间为0、3、6和12个月。患者在日记中记录出血模式,并在治疗期间的对照就诊时评估临床依从性。使用改良的库珀曼指数记录症状。在0、6和12个月的对照就诊时测定血清雌二醇浓度。
LNG-IUD组80%(n = 16)的患者、口服P组第二组67%(n = 14)的患者和阴道P组53%(n = 10)的患者在12个月时无出血。在前3个月中,点滴出血很常见。每组的症状缓解情况良好。LNG-IUD未引起任何严重副作用。LNG-IUD和口服孕酮的依从性良好,但阴道孕酮的依从性不佳。
经皮雌二醇凝胶与LNG-IUD联合是一种合适的激素替代疗法。口服天然孕酮与雌二醇凝胶联合也有用,尽管三分之一的患者出现出血情况使治疗复杂化。由于出血问题,阴道给予天然孕酮不实用。